Noninvasive assessment of cytokine and antimicrobial peptide levels in hidradenitis suppurativa using transdermal analysis patches

por Ardon, C.B., Wang, C., Prens, E.P., van Straalen, K.R.
Publicado 2020

High and discordant prevalences of clinical and sonographic enthesitis in patients with hidradenitis suppurativa

por van Straalen, K.R., Boeren, A.M.P., Wervers, K., Prens, E.P., Vis, M.
Publicado 2020

Lentigo maligna – anatomic location as a potential risk factor for recurrences after non‐surgical treatment

por Greveling, K., van der Klok, Th., van Doorn, M.B.A., Noordhoek Hegt, V., Prens, E.P.
Publicado 2016

The anti‐inflammatory potency of biologics targeting tumour necrosis factor‐α, interleukin (IL)‐17A, IL‐12/23 and CD20 in hidradenitis suppurativa: an ex vivo study

por Vossen, A.R.J.V., Ardon, C.B., van der Zee, H.H., Lubberts, E., Prens, E.P.
Publicado 2019

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study

por Prens, L.M., Bouwman, K., Aarts, P., Arends, S., van Straalen, K.R., Dudink, K., Horváth, B., Prens, E.P.
Publicado 2021

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers

por Vossen, A.R.J.V., van der Zee, H.H., Davelaar, N., Mus, A.M.C., van Doorn, M.B.A., Prens, E.P.
Publicado 2018

Complement activation in Hidradenitis suppurativa: Covert low-grade inflammation or innocent bystander?

por van Straalen, K. R., Dudink, K., Aarts, P., van der Zee, H. H., van den Bosch, T. P. P., Giang, J., Prens, E. P., Damman, J.
Publicado 2022

Primary alterations during the development of hidradenitis suppurativa

por Dajnoki, Z., Somogyi, O., Medgyesi, B., Jenei, A., Szabó, L., Gáspár, K., Hendrik, Z., Gergely, P., Imre, D., Póliska, S., Törőcsik, D., Zouboulis, C.C., Prens, E.P., Kapitány, A., Szegedi, A.
Publicado 2021

Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials

por Jemec, G.B.E., Okun, M.M., Forman, S.B., Gulliver, W.P.F., Prens, E.P., Mrowietz, U., Armstrong, A.W., Geng, Z., Gu, Y., Williams, D.A., Teixeira, H.D., Kimball, A.B.
Publicado 2019

A novel nicastrin mutation in a three‐generation Dutch family with hidradenitis suppurativa: a search for functional significance

por Vossen, A.R.J.V., van Straalen, K.R., Swagemakers, S.M.A., de Klein, J.E.M.M., Stubbs, A.P., Venter, D.J., van der Zee, H.H., van der Spek, P.J., Prens, E.P.
Publicado 2020

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group

por Zouboulis, C.C., Bechara, F.G., Dickinson‐Blok, J.L., Gulliver, W., Horváth, B., Hughes, R., Kimball, A.B., Kirby, B., Martorell, A., Podda, M., Prens, E.P., Ring, H.C., Tzellos, T., van der Zee, H.H., van Straalen, K.R., Vossen, A.R.J.V., Jemec, G.B.E.
Publicado 2018

Highlights of the updated Dutch evidence‐ and consensus‐based guideline on psoriasis 2017

por van der Kraaij, G.E., Balak, D.M.W., Busard, C.I., van Cranenburgh, O.D., Chung, Y., Driessen, R.J.B., de Groot, M., de Jong, E.M.G.J., Kemperman, P.M.J.H., de Kort, W.J.A., Karsch, S.A., Lamberts, A., Lecluse, L.L.A., van Lümig, P.P.M., Menting, S.P., Prens, E.P., van den Reek, J.M.P.A., Seyger, M.M.B., Thio, H.B., Veldkamp, W.R., Wakkee, M., Nast, A., Jacobs, A., Rosumeck, S., Spuls (Chair), P.I.
Publicado 2019